



## Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, September 15, 2020

### ***JBCPL reports strong results for Q1 FY21 driven by growth in exports, API and chronic therapies in the domestic market, along with lower sales and marketing costs during lockdown***

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) announced its consolidated unaudited financial results for the quarter ended on June 30, 2020 on September 14, 2020.

#### **Key Highlights:**

- India domestic formulations: Cardiac segment reported sales growth of 23.6% YoY whereas acute divisions and contrast media reported de growth of 1.2% YoY due to COVID-19 lockdown.
- Export formulations: ~59% YoY growth in ANDA products and stocking up of medicines during Covid lockdown in several geographies resulted in a strong growth in export formulations.
- Subsidiary Sales: South Africa sales grew by ~40% YoY, primarily driven by higher sales in public markets business. Sales of Russia subsidiary de-grew by ~33% YoY due to the impact of COVID -19 lockdown.
- Profitability: Strong growth in EBITDA during the quarter was primarily driven by higher growth in the export markets and API business along with increased share of higher margin chronic business in the domestic market. Margin expansion was further aided by weakening of INR against USD and lower than normal sales and marketing expenses.

#### **Consolidated Financial Performance:**

Rs. in crores			
Particulars	Jun-20	Jun-19	Growth %
Sales	515	435	18.4%
Other Operating Income	7	11	-35.0%
Total Revenue	522	446	17.1%
Operating EBITDA	155	96	61.9%
Other Income	23	13	80.0%
Profit before tax	157	92	70.8%
Profit after tax	123	64	91.4%

## Sales Performance:

Rs. in crores

Particulars	Jun-20	Jun-19	Growth %
Domestic formulations	224	207	8.6%
Export formulations	198	148	33.7%
API	28	19	47.0%
Subsidiary sales	58	56	4.9%
Other sales	6	5	11.9%
Total sales	515	435	18.4%

\*\*\*\*\*

## About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery systems and formulations, filing of ANDAs and DMFs. Its State-of-the-Art manufacturing facilities are approved by health authorities of important regulated markets.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary and Vice President- Compliance  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 2439 5311

-- x --

### Forward Looking Statements:

*This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*